abstract |
This invention relates to salts of formula (I) where, A is 1 and X is 1 or 2; R1 is C8 to C13 alkyl, C7 to C12 alkoxy, C7 to C12 alkylthio, C10 to C12 1-alkynyl, 10-undecynyloxy, 11-dodecynyl, phenyl-C4 to C10 alkyl, phenyl-C3 to C9 alkoxy, phenylthio-C3 to C9 alkyl with the phenyl unsubstituted or monosubstituted with bromo, chloro, trifluoromethyl, C1 to C4 alkoxy, methylthio or trifluoromethylthio, furyl-C4 to C10 alkyl, trifluoromethyl-C7 to C12 alkyl or cyclohexyl-C4 to C10 alkyl; q is 0, 1 or 2, with the proviso that R1 is not alkylthio or phenylthioalkyl when q is 1 or 2; Y is COR3, C(R4)H(CH2)mCOR3, or (CH2)0-1-C-tetrazolyl; R3 is 0<->, amino, or C1 to C6 alkoxy, R4 is hydrogen, methyl, C1 to C4-alkoxy, fluoro or hydroxy; m is 0, 1, or 2; R is (CH2)nCOR6; n is 0 to 6; R6 is 0<->, amino, or C1 to C6-alkoxy; with the proviso that at least one of Y or R must have an R3 or R6 group respectively which is 0<-> and the use of certain amines to form these salts as a means for selectively crystallizing optical isomers of the leukotriene antagonists recited herein. |